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Abstract 
 
1-cyano-2-methyl-3-({[2-(5-methyl-1H-imidazol-4-yl)ethyl]sulfanyl}methyl)guanidine 
(cimetidine) is a drug that helps in the reduction of stomach acidity, pepsin output reduction and 
promotion of ulcer healing. We carried out molecular docking for six analogous structurally 
diverse 1-cyano-2-methyl-3-({[2-(5-methyl-1H-imidazol-4-yl)ethyl]sulfanyl}methyl)guanidine 
(cimetidine) with cytochrome P450 1A2 using Patchdock and Firedock softwares. Extensive 
structure activity relationship studies was carried out with the substituted derivatives and 
compared with the non-substituted.  These molecules were designed by substituting different 
chemical groups on position 17 of cimetidine. The scoring function (empirical binding free energy) 
was used to estimate the free binding energy of the protein-ligand complex. The binding energy of 
cimetidine was -30.96 kcal/mol. The free binding energies of COOH, COCH3, NO2, CF3 and CONH2 
analogues were -33.12, -31.67, -34.67, -34.73 and -36.58 Kcal/mol respectively. All the 
monosubstituted analogues showed lower values than the non substituted cimetidine. These 
lower values indicate that they inhibit CYP450 functional activity. These results suggest that the 
new inhibitors may cause hepatotoxicity. Synthesis and pre-clinical studies of these 
monosubstituted derivatives with cytochrome P450 1A2 receptors is recommended in order to 
confirm their hepatotoxicity.  
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INTRODUCTION 
Cimetidine, a potent CYP450 enzyme inhibitor. It helps in the reduction of stomach acidity, pepsin 
output reduction and promotion of ulcer healing (Elks, 2014; IDD, 2000, Morton et al., 2015; Yusuf, 
2007). It is mainly used in the treatment of heartburn, peptic ulcer, abomasal and duodenal ulcers, 
drug induced erosive gastritis, duodenal gastric reflux and oesophageal reflux healing (Elks, 2014; 
Morton et al., 2015; Yusuf, 2007; Burchum and Rosenthal, 2014). The use of cimetidine has been 
decreased with the development of other longer acting H2 receptor antagonists with fewer adverse 
effects such as famotidine and ranitidine. The monosubstituted derivative of cimetidine could have 
an improvement with a wider spectrum of activity.  
The monosubstituted derivative of cimetidine could also reduce the side effects of cimetidine such 
as, constipation, rashes, muscle pain at the site of injection, fatigue, dizziness and mental confusion 
(Ritter et al., 2008). The changes in the substituent of cimetidine may be very safe in overdose, 
producing no symptoms even at high overdoses (Dart, 2004). Cimetidine is metabolized through 
S-oxygenation by flavin-containing monooxygenases, specifically FMO1 and FMO3 (Cashman, 
2000). Cimetidine is a potent but not a universal inhibitor of  CYP450 enzyme (Dart, 2004; Lemke 
and Williams, 2008) but it inhibits a broad array of CYP450 isoforms, including CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1, and CYP3A4 (Dart, 2004; Lemke and Williams, 2008; Karalliedde et 
al., 2010) and it is said to be most potent in inhibiting CYP1A2, CYP2D6, and CYP3A4 (Priskorn et 
al., 1997) of which it is described as a moderate inhibitor (Elks, 2014) , and this is notable as these 
three isoenzymes are involved in the majority of CYP450-mediated drug biotransformations 
(Martí nez et al., 1999). As such, cimetidine has the potential for a large number of drug 
interactions (Dart, 2004; Lemke and Williams, 2008; Karalliedde et al., 2010). CYP450 enzymes 
are involved in the elimination of xenobiotic detoxification of harmful carcinogenic substances. 
Cytochrome P450 1A2 receptors are mainly expressed in the human liver and participate in the 
oxidation of drugs.                                         
 
Modern approaches to finding new drugs for therapeutics in man and animals are increasingly 
based on 3-dimensional information about receptors. An effective way to predict the binding 
structure of a substrate in its receptor is docking simulation, which has been successfully used in 
many applications (Lorey et al., 2001; Dixon and Blaney, 1998).  Docking procedures basically aim 
to identify the correct conformation of ligands in the binding pocket of a protein and to predict the 
affinity between the ligand and the protein. In other words, it describes a process by which two 
molecules fit together in a 3-dimensional space (Dipankar et al., 2007). Though still in use 
cimetidine is no longer among the more widely used H2- receptor antagonist. Therefore the aim of 
this research is to determine the substituents that will reduce the inhibition of CYP450 enzyme 
and recommend these monosubstituted derivatives for synthesis and pre-clinical studies. The 
structural formula of cimetidine is shown in Figure 1. 
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Figure 1: Cimetidine structural formula 
 
 
MATERIAL AND METHODS 
 
a- Protein preparation  
The three dimensional structure of Cytochroome P450 receptor was obtained from the Protein 
Data Bank, PDB ID – 2HI4 (Figure 2). The protein structure was subjected to a refinement protocol 
using Molegro Molecular Viewer (Molegro Molecular Viewer, 2012).  
 
b-Designing of structural analogs of Cimetidine 
The structure of cimetidine (Figure 1) was drawn with ACD/ChemSketch software (Advanced 
Chemistry Development, 2008). The structural analogues of cimetidine were developed with 
structural modifications with different substituents. The methyl group at 17 position of cimetidine 
was replaced with COOH, COCH3, NO2, CF3 and CONH2 analogues. The structures were built with 
ACD/ChemSketch software and minimized with Arguslab software (Thompson, 2007).  
 
c-Molecular docking  
Molecular docking was performed using Patchdock software (Duhovny et al., 2002). Patchdock is 
a molecular docking algorithm based on shape complementarity principles. The docking job was 
refined in Firedock software (Mashiach et al., 2008; Andrusier et al., 2007) and processed with 
Molegro Molecular Viewer. Lipinski rule of 5 was evaluated using Sanjeevini: a freely accessible 
web-server for target directed lead molecule discovery (Jayaram et al., 2012). 
 
RESULTS AND DISCUSSION 
Estimated free energy of binding (FEB) of cimetidine and its analogues is shown in Table 1. 
Assessment of drug-likeness of the pre-screened ligand is presented in Table 2. Crystal structure 
of cytochroome P450 receptor is shown in Figure 2, while the docked cimetidine analogues with 
cytochroome P450 receptor are presented in Figures 3 – 8. The Hydrogen bonding, electrostatic 
and steric interactions are depicted in Figures 9 -14. 
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Tabled 1: Estimated free energy of binding (FEB) of 1-cyano-2-methyl-3-({[2-(5-methyl-1H- imi 
dazol-4-yl)ethyl]sulfanyl}methyl)guanidine (cimetidine) and its analogues against cytochrome 
P450 1A2     
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Table 2: Assessment of drug-likeness of 1-cyano-2-methyl-3-({[2-(5-methyl-1H-imidazol-4-yl) 
ethyl]sulfanyl}methyl)guanidine (cimetidine) and its analogues 
 
 
 
Fig 2: Crystal structure of cytochrome P450 1A2(PDB 2HIA) 
 
 
 
Fig 3: Cimetidine docked with cytochrome P450 1A2 
 
 
 
Fig 4: COOH analogue of cimetidine docked with cytochrome P450 1A2 
 
Substituents Molecular 
weight 
Hydrogen 
bond donor 
Hydrogen 
bond 
acceptors: 
Lipophilicity 
LogP 
Molar 
Refractivity 
CH3 250.000 3.000 5.000 1.632 73.720 
COOH 278.000 4.000 7.000 0.715 67.960 
COCH3 277.000 3.000 6.000 0.827 76.093 
NO2 282.000 4.000 7.000 0.715 67.960 
CF3 305.000 3.000 5.000 2.047 73.581 
CONH2 277.000 4.000 7.000 0.844 76.030 
International Journal of Research in Engineering and Applied Sciences(IJREAS) 
Vol. 6 Issue x, Month - 2016 
ISSN(O): 2249-3905, ISSN(P) : 2349-6525 | Impact Factor: 6.573  
 
 
 
International Journal of Research in Engineering & Applied Sciences 
Email:- editorijrim@gmail.com, http://www.euroasiapub.org 
An open access scholarly, online, peer-reviewed, interdisciplinary, monthly, and fully refereed journals 
6 
     
Fig 5: COCH3 analogue of cimetidine docked with cytochrome P450 1A2 
 
 
 
Fig 6: NO2 analogue of cimetidine docked with cytochrome P450 1A2 
 
 
 
Fig 7:  CF3 analogue of cimetidine docked with cytochrome P450 1A2 
 
 
 
Fig 8: CONH2 analogue of cimetidine docked with cytochrome P450 1A2 
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Fig. 9. Hydrogen bonding, electrostatic and steric interactions of CF3 analogue of cimetidine 
docked with cytochrome P450 1A2 
 
 
Fig. 10. Hydrogen bonding, electrostatic and steric interactions of COOH analogue of cimetidine 
docked with cytochrome P450 1A2 
 
 
Fig. 11. Hydrogen bonding, electrostatic and steric interactions of CONH2 analogue of cimetidine 
docked with cytochrome P450 1A2 
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Fig. 12. Hydrogen bonding, electrostatic and steric interactions of COCH3 analogue of cimetidine 
docked with cytochrome P450 1A2 
 
 
Fig. 13. Hydrogen bonding, electrostatic and steric interactions of NO2 analogue of cimetidine 
docked with cytochrome P450 1A2 
 
 
 
Fig. 14. Hydrogen bonding, electrostatic and steric interactions of cimetidine docked with 
cytochrome P450 1A2 
 
The docking structures of all the compounds showed that they bind in a very similar pattern with 
the active site of cytochrome P450 receptor, as is evident from the superposition of all the six 
analogues in Figures 3 - 8. The hydrogen bonding, electrostatic and steric interactions of 
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cimetidine and its analogues with cytochrome P450 1A2 occurred at Met 453, Met 449, Met 448, 
Leu 91, Lys 447, Glu 461, Glu 446, Ser 445, Lys 442, Leu 373, Glu 369, Arg 362, Tyr 495, Ser 231, 
Lys 59, Glu 233, Pro 61, Ser 232, Gly 232, Asn 234, Lys 465 and Arg 95.  
The calculated free energy of binding of the six cimetidine analogues was -30.96, -33.12, -31.67, -
34.67, -34.73 and -36.58 Kcal/mol (Table 1). This confirms that the structural modification 
implemented in this study is significantly related to their activity. Also, this proved the 
reasonability and reliability of the docking results. It can be seen that substitution of NH2 
functional group of cimetidine with CH3, COOH, COCH3, NO2 ,CF3 and CONH2 analogues at positions 
17 lead to an increase in the binding affinity of modified analogues which is even more intense 
than that of cimetidine. The binding energy of cimetidine was -30.96 kcal/mol. These results 
clearly indicated that before synthesis and biochemical testing of new analogues one can use 
molecular docking based methods for qualitative assessment of relative binding affinities for 
speeding up drug discovery process by eliminating less potent compounds from synthesis.  
 
Lipinski rule of 5 (Lipinski, 2004) helps in distinguishing between drug like and non-drug like 
molecules. It predicts high probability of success or failure due to drug likeness for molecules 
complying with 2 or more of the following rules: Molecular mass less than 500 Dalton; High 
lipophilicity (expressed as LogP less than 5);Less than 5 hydrogen bond donors ;Less than 10 
hydrogen bond acceptors ;Molar refractivity should be between 40-130. Cimetidine and its 
modified analogues obeyed the Lipinski rule of 5 (Table 2). These filters help in early preclinical 
development and could help avoid costly late-stage preclinical and clinical failures. 
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